InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
18,978.00
(
-1.19%
)
Dow Jones
39,411.21
(
0.67%
)
Brent Oil
85.20
(
-0.09%
)
Bitcoin
60,536.05
(
0.46%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 167

Sunday, 05/20/2018 5:25:15 PM

Sunday, May 20, 2018 5:25:15 PM

Post# of 438
SNDX 's lead program is in a Ph3 study for a highly-difficult-to-treat breast cancer.

Entinostat's Ph3 results will be out Q-3/2018.

Entinostat is also being assessed in a combination with other flagship drugs.

Cash runway is only into H-1/2019.

This will become a struggling biotech if the Ph3 lung cancer results are weak.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up